TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06657768: A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 128 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$5,197,648

Rescue Site Savings

+$3,429,920

Unlock Full NCT06657768 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06657768 Rescue Dossier →